As such, therapeutics causing PP2A inhibition can block this response to DNA damage forcing cancer cells with damaged DNA to undergo cell cycle progression, prevent the release of cells from DNA damage repair, etc. and ultimately cause cytotoxicity due to accumulation of damaged cells and unstable chromatin [8, 102]. This evidence concerns the gene PTPA and cancer.